Available evidence now suggests that magnesium sulfate administered to mothers prior to
early preterm delivery reduces the risk of cerebral palsy in surviving neonates. The …

Objective To study the effect of antenatal magnesium sulphate (MgSO4) on cerebral palsy
(CP) in a manner that also provides adequate power for a linked trial sequential analysis …

Importance Intravenous magnesium sulfate administered to pregnant individuals before birth
at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …

Background: Preterm birth is one that occurs at< 37 weeks of gestation or less than 258 days
of gestation. WHO classifies premature infants into three categories, Extremely preterm (< …

Background Survival of preterm infants has improved drastically. In addition to significant
contribution to neonatal mortality, impact of prematurity among survivors may continue …

Intrapartum magnesium for prevention of cerebral palsy: cont... : Current Opinion in Obstetrics
and Gynecology Intrapartum magnesium for prevention of cerebral palsy: continuing …

Magnesium sulfate in some dosage given before very preterm pregnancy delivery is
beneficial for fetal neuroprotection. The exact dose, duration, and timing of administration to …

This is a comment on" Antenatal magnesium sulphate for the prevention of cerebral palsy in
infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial." …

Objective: Previous studies demonstrated that magnesium sulfate is associated with better
neurological outcome and decreased cerebral palsy rates in preterm newborns. The aim of …

OBJECTIVE: Clinical trials support the efficacy and safety of magnesium sulfate for cerebral
palsy prevention. We evaluated the implementation of a clinical protocol for the use of …